Progyny, Inc. Announces Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Progyny (PGNY) Tops Q3 EPS by 1c, Revenues Beat; Offers Q4 & FY19 EPS/Revenue Guidance
December 4, 2019 4:08 PM ESTProgyny (NASDAQ: PGNY) reported Q3 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $61.2 million versus the consensus estimate of $60.77 million.
Progyny has redefined the market for employer-sponsored fertility benefits, demonstrating that it is possible to simultaneously create a great patient experience, generate superior clinical outcomes, and provide for a more efficient use of employer healthcare dollars to address a health condition that affects millions, said David Schlanger, Chief Executive Officer of Progyny. Our vision is to ensure that anyone can have a child, and we are... More



